Mechanistic convergence of the TIGIT and PD-1 inhibitory pathways necessitates co-blockade to optimize anti-tumor CD8<sup>+</sup> T cell responses.

Banta KL, Xu X, Chitre AS, Au-Yeung A, Takahashi C, O'Gorman WE, Wu TD, Mittman S, Cubas R, Comps-Agrar L, Fulzele A, Bennett EJ, Grogan JL, Hui E, Chiang EY, Mellman I. · 2022

Read Mechanistic convergence of the TIGIT and PD-1 inhibitory pathways necessitates co-blockade to optimize anti-tumor CD8<sup>+</sup> T cell responses. by Banta KL, Xu X, Chitre AS, Au-Yeung A, Takahashi C, O'Gorman WE, Wu TD, Mittman S, Cubas R, Comps-Agrar L, Fulzele A, Bennett EJ, Grogan JL, Hui E, Chiang EY, Mellman I. (2022) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc9287124.txt.

Introduction

Banta and co-authors explain why blocking both TIGIT and PD-1 works better than either alone against tumors. Both are brake receptors on T cells, and dual blockade shows early promise in patients. The team studied how each brake controls the gas-pedal receptors CD28 and CD226. Tests ran in mouse tumors and in lung cancer patient samples.

PD-1 was found to damp both CD226 and CD28 signals directly. TIGIT instead blocks CD226 by stealing its shared binding partner. Either drug lost effect when CD226 was absent. CD226 levels also tracked with patient benefit from anti-PD-L1 therapy. Full revival of CD226 signaling needs both brakes off. That gives a clear reason for combined treatment in the clinic.

Catalog record

CREATORBanta KL, Xu X, Chitre AS, Au-Yeung A, Takahashi C, O'Gorman WE, Wu TD, Mittman S, Cubas R, Comps-Agrar L, Fulzele A, Bennett EJ, Grogan JL, Hui E, Chiang EY, Mellman I.
YEAR2022
COLLECTIONPAPERS
FORMATTXT
FILE SIZE86 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC9287124

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Mechanistic convergence of the TIGIT and PD-1 inhibitory pathways necessitates co-blockade to optimize anti-tumor CD8+ T cell responses By Karl L. Banta, Xiaozheng Xu, Avantika S. Chitre, Amelia Au-Yeung, Chikara Takahashi, William E. O’Gorman, Thomas D. Wu, Stephanie Mittman, Rafael Cubas, Laetitia Comps-Agrar, Amit Fulzele, Eric J. Bennett Published in: Immunity DOI: 10.1016/j.immuni.2022.02.005 ABSTRACT SUMMARY Dual blockade of the PD-1 and TIGIT coinhibitory receptors on T cells shows promising early results in cancer patients. Here, we studied the mechanisms whereby PD-1 and/or TIGIT blockade modulate anti-tumor CD8+ T cells. Although PD-1 and TIGIT are thought to regulate different costimulatory receptors (CD28 and CD226), effectiveness of PD-1 or TIGIT inhibition in preclinical tumor models was reduced in the absence of CD226. CD226 expression associated with clinical benefit in patients with non-small cell lung carcinoma (NSCLC) treated with anti-PD-L1 antibody atezolizumab. CD226 and CD28 were co-expressed on NSCLC infiltrating CD8+ T cells poised for expansion. Mechanistically, PD-1 inhibited phosphorylation of both CD226 and CD28 via its ITIM-containing intracellular domain (ICD); TIGIT’s ICD was dispensable, with TIGIT restricting CD226 co-stimulation by blocking interaction with their common ligand PVR (CD155). Thus, full restoration of CD226 signaling, and optimal anti-tumor CD8+ T cell responses, requires blockade of TIGIT and PD-1, providing a mechanistic rationale for combinatorial targeting in the clinic. INTRODUCTION T cell inhibitory receptors, such as CTLA-4, PD-1, and TIGIT, are essential for limiting immunopathology and terminating effective immune responses, but also can restrain effective anti-tumor immune responses. Immunotherapeutic antibodies directed against these inhibitory receptors, including ipilimumab, nivolumab, pembrolizumab, atezolizumab, and tiragolumab, aim to enhance and reinvigorate antigen-specific T cell effector responses and have elicited clear or promising activity in cancer patients (Chen and Mellman, 2013). Although durable, responses have been limited to a minority of patients, creating considerable interest in exploring combinations of these antibodies with each other or with other therapeutic agents. Given the emerging complexities with regards to cell type expression, regulation, and function of PD-1, CTLA-4, and TIGIT (Yost et al., 2021), a greater understanding of the mechanisms associated with each may provide clues as to which combinations will be most effective. Each coinhibitory receptor acts to regulate the activity of an important costimulatory receptor. CTLA-4 is well known to counteract CD28, and more recently, CD28 was also shown to be regulated by PD-1 (Hui et al., 2017). Indeed, inhibition of CD28 abolishes the ability of CD8+ T cells to respond to PD-1 blockade in vivo (Kamphorst et al., 2017). Although less well studied, CD226 is a costimulatory receptor regulated by TIGIT and exhibits multifaceted functions in anti-tumor CD8+ T cell responses (Gilfillan et al., 2008; Manes and Pober, 2011; Ralston et al., 2004; Shibuya et al., 1999, 2003; Shirakawa et al., 2005). The importance of CD226 in regulating anti-tumor responses is demonstrated in mouse tumor models where use of a CD226-neutralizing monoclonal antibody (mAb) abrogates the efficacy of combining mAbs against PD-L1 and TIGIT (Johnston et al., 2014). Furthermore, CD8+ T cells with decreased or loss of CD226 expression exhibit characteristics of dysfunction, and such cells are present in tumors and correlate with resistance to cancer immunotherapy (Braun et al., 2020; Weulersse et al., 2020). Thus, simultaneous blockade with anti-PD-(L)1 and anti-TIGIT mAbs may coordinately inhibit the negative signals of PD-1 and TIGIT by facilitating the activities of their respective client costimulatory receptors. It nevertheless remains unclear why targeting PD-1 and TIGIT pathways appear to synergize, especially since PD-(L)1 mAb, but not TIGIT mAb, can often yield complete responses on its own. The CD28:CTLA-4 and CD226:TIGIT receptor pairs are highly analogous. CTLA-4 expression increases immediately following TCR engagement and attenuates CD28 signals by outcompeting CD28 for binding to, or depleting, their shared ligands (CD80, CD86) (Qin et al., 2019; Sansom and Walker, 2006; Wei et al., 2018). TIGIT expression increases following T cell activation and attenuates activating signals through CD226 by outcompeting CD226 for binding to their shared ligands PVR (CD155) and PVRL2 (CD112) (Manieri et al., 2017). Recent evidence, however, suggests that inhibition of costimulatory molecules is more sophisticated than originally thought. Both CD28 and CD226 are not only regulated by their respective inhibitory receptors (i.e., CTLA-4 and TIGIT) but may also be dephosphorylated by the Shp2 phosphatase that is recruited to the PD-1 intracellular domain (ICD) following T cell activation and phosphorylation by Lck (Hui et al., 2017; Wang et al., 2018). TIGIT and PD-1 are often considered as markers of exhausted CD8+ T cells, enabling the maintenance of a quiescent state in these cells. However, expression of these inhibitory receptors is increased upon T cell activation and exhibits complex patterns among various T cell subsets (Chauvin and Zarour, 2020; Hashimoto et al., 2018; Wu et al., 2020; Zarour, 2016). Rather than maintaining exhaustion, there is increasing evidence that PD-1 acts to restrain the expansion of antigen-specific T cells at the priming or expansion step (Im et al., 2016; Miller et al., 2019; Oh et al., 2020; Siddiqui et al., 2019; Utzschneider et al., 2016; Wu et al., 2016; Yost et al., 2021). TIGIT and PD-1 may also be co-expressed by CD103+ CD8+ resident memory T cells (Trm), a T cell subpopulation that mediates anti-tumor immunity that may be derived from stem cell-like memory T (Tscm) or effector T (Teff) cells (Corgnac et al., 2020; Craig et al., 2020; Park et al., 2019). In this study, we investigated how PD-(L)1 or TIGIT blockade regulated CD8+ T cell responses against tumors. CD226 expression was required for efficacy of PD-(L)1 or TIGIT targeted therapies and PD-1 and TIGIT converged on CD226 to disable activation of this key costimulatory receptor. Thus, these two inhibitory receptors are interdependent, suggesting that their coordinate inhibition is required to elicit optimal T cell activity. RESULTS Absence of CD226 diminishes anti-tumor efficacy with PD-1 or TIGIT checkpoint blockade We previously observed that the anti-tumor efficacy of combined anti-PD-L1 and anti-TIGIT blockade in mice is abrogated by a CD226-blocking mAb (Johnston et al., 2014), suggesting that costimulation by both CD226 and CD28 is required to overcome inhibition by PD-1 and TIGIT. To understand this relationship in greater detail, we monitored the growth of syngeneic CT26 tumor cells in wild-type (WT) or Cd226−/− mice. To focus the analysis selectively on TIGIT or PD-1, we examined tumor growth in the prevention setting (i.e., the mAb was administered shortly after tumor implantation) where both anti-TIGIT and anti-PD-L1 exhibit single agent activity; in the therapeutic setting, anti-TIGIT is most effective when combined with anti-PD-L1. As shown in Figure 1A and in agreement with recent results (Weulersse et al., 2020), WT mice that received anti-PD-1 or anti-TIGIT exhibited reduced tumor growth compared to animals treated with a control antibody. However, the therapeutic benefit of either anti-PD-1 or anti-TIGIT was reduced or lost in Cd226−/− mice even though signaling via CD28 remained intact. As CD226 deficiency is known to alter the transcriptional profile of CD8+ T cells affecting the effector program (Braun et al., 2020; Du et al., 2018; Weulersse et al., 2020), we also assessed the requirement for CD226 to mediate target cell killing. When OT-I CD8+ T cells from WT or Cd226−/− mice were co-cultured with OVA (SIINFEKL) peptide loaded B16F10 melanoma cells expressing or deficient in both PVR and

Read the complete text